Two Sigma Investments LP Increases Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Two Sigma Investments LP raised its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 136.1% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 297,443 shares of the biopharmaceutical company's stock after purchasing an additional 171,480 shares during the quarter. Two Sigma Investments LP owned approximately 0.10% of Amicus Therapeutics worth $2,802,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Covestor Ltd increased its position in shares of Amicus Therapeutics by 114.9% during the fourth quarter. Covestor Ltd now owns 4,325 shares of the biopharmaceutical company's stock worth $41,000 after buying an additional 2,312 shares during the period. R Squared Ltd bought a new stake in Amicus Therapeutics during the fourth quarter valued at $79,000. KBC Group NV grew its holdings in Amicus Therapeutics by 44.4% during the 4th quarter. KBC Group NV now owns 10,154 shares of the biopharmaceutical company's stock worth $96,000 after acquiring an additional 3,120 shares during the period. Sciencast Management LP bought a new position in shares of Amicus Therapeutics in the 4th quarter worth about $100,000. Finally, Stephens Inc. AR bought a new position in shares of Amicus Therapeutics in the 4th quarter worth about $101,000.

Analyst Upgrades and Downgrades

FOLD has been the subject of several recent analyst reports. UBS Group raised their target price on Amicus Therapeutics from $21.00 to $22.00 and gave the stock a "buy" rating in a research note on Friday, May 2nd. Wells Fargo & Company reduced their price objective on shares of Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating for the company in a research report on Thursday, February 20th. Needham & Company LLC reiterated a "hold" rating on shares of Amicus Therapeutics in a research report on Thursday, February 20th. Wall Street Zen cut shares of Amicus Therapeutics from a "buy" rating to a "hold" rating in a report on Monday, May 5th. Finally, The Goldman Sachs Group decreased their price target on shares of Amicus Therapeutics from $12.00 to $9.00 and set a "neutral" rating for the company in a research note on Friday, May 2nd. Four investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to MarketBeat.com, Amicus Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $16.22.

Amicus Therapeutics Stock Down 2.6%

Shares of FOLD traded down $0.16 during trading hours on Wednesday, reaching $6.10. 4,522,170 shares of the stock traded hands, compared to its average volume of 2,910,781. Amicus Therapeutics, Inc. has a 52 week low of $5.81 and a 52 week high of $12.65. The company has a current ratio of 3.39, a quick ratio of 2.42 and a debt-to-equity ratio of 2.01. The stock has a fifty day simple moving average of $6.69 and a 200 day simple moving average of $8.50. The company has a market cap of $1.88 billion, a price-to-earnings ratio of -33.89, a PEG ratio of 1.51 and a beta of 0.64.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.